EUCTR2007-004056-36-GB进行中（未招募）不适用
A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. (code: Sched2) - Sched2
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •No contraindications to vaccination as specified in the Green Book” – Immunisation Against Infectious Disease, HMSO.
- •Written informed consent obtained from the parent or legal guardian of the infant
- •Infant aged no less than 7 weeks exactly, and no more than 11 weeks 6 days
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccinesThis study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.MedDRA version: 9.1 Level: LLT Classification code 10058580 Term: Human papilloma virus serology testEUCTR2008-006773-32-GBHealth Protection Agency84
进行中（未招募）
不适用
Study on the evaluation of the short-term and long-term response to the anti-flu vaccination Inflexal V in elderly patientsEUCTR2011-003188-31-ITCRUCELL SWITZERLAND AG
进行中（未招募）
不适用
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years - Pediatric Rapid TBE Immunization StudyEvaluation of Immunogenicity of a TBE (Tick Borne Encephalitis) Vaccine in previously unvaccinated children aged 1 to below 15 yearsMedDRA version: 12.1Level: LLTClassification code 10043847Term: Tick-borne viral encephalitisEUCTR2010-020097-42-ATBaxter Innovations GmbH240
进行中（未招募）
1 期
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25 ml JUNIOR in Healthy Children aged 3 - 15 YearsPrevention of Tick-born encephalitis (TBE). The rapid immunization schedule recommended in the current SPC for FSME-IMMUN 0.5 ml (Day 0, Day 14) has been used in Austria for 20 years. FSME-IMMUN 0.25 ml was first administered in clinical trials in the year 2001 and the rapid immunization schedule is recommended for children ranging 1 to 16 years of age. However, limited data on immunogenicity when using the rapid immunization schedule in children exist.MedDRA version: 9.1Level: LLTClassification code 10043847Term: Tick-borne viral encephalitisEUCTR2007-000810-35-CZBIOVOMED300
已完成
4 期
to evaluate the Immunogenicity and Safety of Typbar-TCV® in AdultsCTRI/2019/10/021823Bharat Biotech International Ltd300